Stocks
Intra-Cellular Therapies (ITCI) EBITDA US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -230.7 | -285.2 | -263.0 | -158.9 | -116.7 | -116.2 | ||
| Changes by years, y/y, % | +50% | +24% | -8% | -40% | -27% | -5.3% | |||
Intra-Cellular Therapies. EBITDA US GAAP, bln rub
Intra-Cellular Therapies. EBITDA US GAAP, changes, %
Intra-Cellular Therapies. EBITDA US GAAP, sum by quarters, bln rub
Intra-Cellular Therapies (ITCI) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | LTM ? | |||
| EBITDA, bln rub | ? | -34.0 | -20.8 | -27.6 | -38.7 | -29.1 | -116.2 | |
| Changes by years, y/y, % | -28% | -57% | -41% | +31% | -14% | |||
| Changes by quarters, q/q, % | +15% | -39% | +33% | +40% | -25% | |||
